Generative AI in Healthcare Market Outlook:
Generative AI in Healthcare Market size was valued at USD 2.79 billion in 2025 and is set to exceed USD 50.92 billion by 2035, expanding at over 33.7% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of generative AI in healthcare is estimated at USD 3.64 billion.
The ability of generative AI to produce inventive and dependable data has drawn attention from the market. This has improved patient reactions, allowed for better diagnosis, and produced synthetic datasets for training and testing. According to the Survey, roughly 75% of significant healthcare organizations are presently experimenting with or planning to scale generative AI. This indicates that the healthcare sector is heavily investing in exposing the transformative possibilities of generative AI.
In addition to these, the market will expand considerably as a result of the application of generative AI in medication research and development. The process of finding new drugs is greatly accelerated by generative AI technology, which creates novel compounds and predicts their possible biological actions using deep learning algorithms. Generative artificial intelligence (AI) shortens the time and expense often involved in the discovery of new medications by modeling and forecasting the interactions between chemicals and biological targets. Additionally, it has made it possible for scientists to investigate large, previously unreachable chemical regions, which has resulted in the discovery of intriguing treatment possibilities for conditions ranging from cancer to uncommon genetic abnormalities.
